Slide 1: Investor Presentation Q1 FY15 Earnings Release
Investor Presentation Q1 FY 15 Earnings Release 14 Aug 2014 Investor Presentation 1
Slide 2: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results t
Slide 3: Business Update
Business Update Topline growth of 7.3% QoQ ▪ Strong India business performance - 17% vs. ~10% for the industry ▪ Tender wins in South Africa ▪ North America and Europe plans on track Increased EBITDA margins QoQ – 20% as compared to 16% in Q4 FY 14 ▪ Positive product mix impact ▪ Focused cost manage
Slide 4: Financial Performance Summary – Q1 FY15
Financial Performance Summary – Q1 FY 15 Quarterly Numbers Standalone Consolidated Actuals Actuals vs Q1 FY 14 vs Q4 FY 14 vs Q1 FY 14 vs Q4 FY 14 (Rs Cr.) (Rs Cr.) Revenue 2,474 -0.5% 7.4% 2,720 8.3% 7.3% Domestic sales 1,291 16.9% 45.6% 1,289 17.0% 41.9% Exports sales 1,111 -16.2% -7.7% 1,358 10.5
Slide 5: Performance Summary (1/2)
Performance Summary (1/2) Area Highlights • Consolidated Sales: Rs 2,720 cr, 8.3% above Q1 FY 14 and 7.3% above Q4 FY 14. • EBITDA : Rs 542 cr, 21% below Q1 FY 14 (when there was a one off impact of Dymista) and 32% above Q4 FY 14. Financial • EBITDA margin: 20% as compared to 16% in Q4 FY 14 Perfor
Slide 6: Performance Summary (2/2)
Performance Summary (2/2) Area Highlights • Front end presence in Yemen and Sri Lanka, integration underway • Continue to assess opportunities to build front ends in select international markets Strategy • BioQuiddity partnership in Europe for selling post-surgical pain management products • Darbopo
Slide 7: Thank You
Thank You Investor Presentation 7